Neprilysin Inhibition in Heart Failure: Mechanisms and Substrates Beyond Modulating Natriuretic Peptides
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The autonomic nervous system, the renin–angiotensin–aldosterone system, and the natriuretic peptide system represent critical regulatory pathways in heart failure and as such have been the major targets of pharmacological development. The introduction and approval of angiotensin receptor neprilysin inhibitors (ARNi) have broadened the available drug treatments of patients with chronic heart failure with reduced ejection fraction. Neprilysin catalyses the degradation of a number of vasodilator peptides, including the natriuretic peptides, bradykinin, substance P, and adrenomedullin, as well as vasoconstrictor peptides, including endothelin-1 and angiotensin I and II. We review the multiple, potentially competing, substrates for neprilysin inhibition, and the resultant composite clinical effects of ARNi therapy. A mechanistic understanding of this novel therapeutic class may provide important insights into the expected on-target and off-target effects when this agent is more widely prescribed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Packer, M., McMurray, J. J. V., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013748 · Cited by 673
Self-citationIncidence and Characteristics of Angioedema Associated With Enalapril
Kostis, J. B., Kim, H. J., Rusnak, J., Casale, T., Kaplan, A., Corren, J., & Levy, E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.14.1637 · Cited by 291
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies
Vaduganathan, M., Butler, J., Pitt, B., & Gheorghiade, M. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002271 · Cited by 38
Self-citation
Cited by
Goetze, J. P., Bruneau, B. G., Ramos, H. R., Ogawa, T., de Bold, M. K., & de Bold, A. J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0381-0 · Cited by 531
Metadata
- Authors
- D'Elia, E., Iacovoni, A., Vaduganathan, M., Lorini, F. L., Perlini, S., & Senni, M.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-03-21
- Volume
- 19
- Issue
- 6
- Pages
- 710-717
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2602877283
- Cited by
- 169
- References
- 7
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neprilysin Inhibition in Heart Failure: Mechanisms and Substrates Beyond Modulating Natriuretic Peptides. https://app.cochat.ai/papers/10.1002/ejhf.799
- The paper
- D'Elia, E., Iacovoni, A., Vaduganathan, M., Lorini, F. L., Perlini, S., & Senni, M. (2017). Neprilysin Inhibition in Heart Failure: Mechanisms and Substrates Beyond Modulating Natriuretic Peptides. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.799
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.